TY - JOUR
T1 - Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation
AU - Gammie, James S.
AU - Chu, Michael W.A.
AU - Falk, Volkmar
AU - Overbey, Jessica R.
AU - Moskowitz, Alan J.
AU - Gillinov, Marc
AU - Mack, Michael J.
AU - Voisine, Pierre
AU - Krane, Markus
AU - Yerokun, Babatunde
AU - Bowdish, Michael E.
AU - Conradi, Lenard
AU - Bolling, Steven F.
AU - Miller, Marissa A.
AU - Taddei-Peters, Wendy C.
AU - Jeffries, Neal O.
AU - Parides, Michael K.
AU - Weisel, Richard
AU - Jessup, Mariell
AU - Rose, Eric A.
AU - Mullen, John C.
AU - Raymond, Samantha
AU - Moquete, Ellen G.
AU - O’Sullivan, Karen
AU - Marks, Mary E.
AU - Iribarne, Alexander
AU - Beyersdorf, Friedhelm
AU - Borger, Michael A.
AU - Geirsson, Arnar
AU - Bagiella, Emilia
AU - Hung, Judy
AU - Gelijns, Annetine C.
AU - O’Gara, Patrick T.
AU - Ailawadi, Gorav
N1 - Publisher Copyright:
Copyright © 2021 Massachusetts Medical Society.
PY - 2022/1/27
Y1 - 2022/1/27
N2 - BACKGROUND Tricuspid regurgitation is common in patients with severe degenerative mitral regurgitation. However, the evidence base is insufficient to inform a decision about whether to perform tricuspid-valve repair during mitral-valve surgery in patients who have moderate tricuspid regurgitation or less-than-moderate regurgitation with annular dilatation. METHODS We randomly assigned 401 patients who were undergoing mitral-valve surgery for degenerative mitral regurgitation to receive a procedure with or without tricuspid annuloplasty (TA). The primary 2-year end point was a composite of reoperation for tricuspid regurgitation, progression of tricuspid regurgitation by two grades from baseline or the presence of severe tricuspid regurgitation, or death. RESULTS Patients who underwent mitral-valve surgery plus TA had fewer primary-end-point events than those who underwent mitral-valve surgery alone (3.9% vs. 10.2%) (relative risk, 0.37; 95% confidence interval [CI], 0.16 to 0.86; P=0.02). Two-year mortality was 3.2% in the surgery-plus-TA group and 4.5% in the surgery-alone group (relative risk, 0.69; 95% CI, 0.25 to 1.88). The 2-year prevalence of progression of tricuspid regurgitation was lower in the surgery-plus-TA group than in the surgery-alone group (0.6% vs. 6.1%; relative risk, 0.09; 95% CI, 0.01 to 0.69). The frequencies of major adverse cardiac and cerebrovascular events, functional status, and quality of life were similar in the two groups at 2 years, although the incidence of permanent pacemaker implantation was higher in the surgery-plus-TA group than in the surgery-alone group (14.1% vs. 2.5%; rate ratio, 5.75; 95% CI, 2.27 to 14.60). CONCLUSIONS Among patients undergoing mitral-valve surgery, those who also received TA had a lower incidence of a primary-end-point event than those who underwent mitral-valve surgery alone at 2 years, a reduction that was driven by less frequent progression to severe tricuspid regurgitation. Tricuspid repair resulted in more frequent permanent pacemaker implantation. Whether reduced progression of tricuspid regurgitation results in long-term clinical benefit can be determined only with longer follow-up.
AB - BACKGROUND Tricuspid regurgitation is common in patients with severe degenerative mitral regurgitation. However, the evidence base is insufficient to inform a decision about whether to perform tricuspid-valve repair during mitral-valve surgery in patients who have moderate tricuspid regurgitation or less-than-moderate regurgitation with annular dilatation. METHODS We randomly assigned 401 patients who were undergoing mitral-valve surgery for degenerative mitral regurgitation to receive a procedure with or without tricuspid annuloplasty (TA). The primary 2-year end point was a composite of reoperation for tricuspid regurgitation, progression of tricuspid regurgitation by two grades from baseline or the presence of severe tricuspid regurgitation, or death. RESULTS Patients who underwent mitral-valve surgery plus TA had fewer primary-end-point events than those who underwent mitral-valve surgery alone (3.9% vs. 10.2%) (relative risk, 0.37; 95% confidence interval [CI], 0.16 to 0.86; P=0.02). Two-year mortality was 3.2% in the surgery-plus-TA group and 4.5% in the surgery-alone group (relative risk, 0.69; 95% CI, 0.25 to 1.88). The 2-year prevalence of progression of tricuspid regurgitation was lower in the surgery-plus-TA group than in the surgery-alone group (0.6% vs. 6.1%; relative risk, 0.09; 95% CI, 0.01 to 0.69). The frequencies of major adverse cardiac and cerebrovascular events, functional status, and quality of life were similar in the two groups at 2 years, although the incidence of permanent pacemaker implantation was higher in the surgery-plus-TA group than in the surgery-alone group (14.1% vs. 2.5%; rate ratio, 5.75; 95% CI, 2.27 to 14.60). CONCLUSIONS Among patients undergoing mitral-valve surgery, those who also received TA had a lower incidence of a primary-end-point event than those who underwent mitral-valve surgery alone at 2 years, a reduction that was driven by less frequent progression to severe tricuspid regurgitation. Tricuspid repair resulted in more frequent permanent pacemaker implantation. Whether reduced progression of tricuspid regurgitation results in long-term clinical benefit can be determined only with longer follow-up.
UR - http://www.scopus.com/inward/record.url?scp=85119979957&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa2115961
DO - 10.1056/NEJMoa2115961
M3 - Article
AN - SCOPUS:85119979957
SN - 0028-4793
VL - 386
SP - 327
EP - 339
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 4
ER -